foxo4 dri senolytic peptide human trial 2024 2025

foxo4 dri senolytic peptide human trial 2024 2025 Frontiers Peptide inhibitors targeting FOXO4-p53 interactions

Name: foxo4 dri senolytic peptide human trial 2024 2025 Frontiers Peptide inhibitors targeting FOXO4-p53 interactions
Brand: ldesquadrias.com.br
SKU: 94199783445
Price: 20.11 USD
Availability: InStock
Rating: 4.1386 (15 reviews)

Peptide inhibitors targeting FOXO4 p53 interactions and inducing senescent cancer cell specific apoptosis bioRxiv FOXO4 DRI improves spermatogenesis in aged mice through reducing senescence associated secretory phenotype secretion from Leydig cells ScienceDirect Heterogeneity of Cellular Senescence, Senotyping, and Targeting by Senolytics and Senomorphics in Lung Diseases[v1] Computational design of peptide targeting FOXO4. a, Domains of FOXO4 Download Scientific Diagram Molecular modelling of the FOXO4 TP53 interaction to design senolytic peptides for the elimination of senescent cancer cells ScienceDirect Frontiers FOXO4 DRI regulates endothelial cell senescence via the P53 signaling pathway

SKU: 94199783445 · From ldesquadrias.com.br

4.1

USD20.11 USD62.11

Pay in 4 interest-free payments of $5.03 Learn more

Shipping Estimate
USA

USA

CAN

Ships within 48 hours · Estimated delivery Aug 3 - Aug 8

Description

By increasing telomerase activity, epithalon theoretically allows cells to replicate more times before reaching senescence

On the advantage side, GHK-Cu demonstrates superior stability compared to synthetic growth factors, with a half-life of 4.2 hours in physiological conditions versus 1.8 hours for EGF